

Market Announcement

1 October 2020

Mesoblast Limited (ASX: MSB) – Trading Halt

Description

The securities of Mesoblast Limited ('MSB') will be placed in trading halt at the request of MSB, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 5 October 2020 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)



Mesoblast Limited

Corporate Headquarters Level 38

55 Collins Street Melbourne, Victoria 3000 **AUSTRALIA**

T +61 3 9639 6036

F +61 3 9639 6030

United States Operations

505 Fifth Avenue Third Floor New York, NY 10017 USA

T +1 212 880 2060

F +1 212 880 2061

Asia

20 Biopolis Way #05-01 Centros Biopreneur 3 SINGAPORE 138668

T +65 6570 0635

F +65 6570 0176

info@mesoblast.com www.mesoblast.com

1 October 2020

Ms Melissa Kostopoulos Adviser, Listings Compliance (Melbourne) **ASX Compliance Pty Limited** Level 4 Rialto North Tower 525 Collins Street Melbourne VIC 3000

Copy: tradinghaltsmelbourne@asx.com.au

Dear Melissa

Request for trading halt for Mesoblast Limited (ASX: MSB)

Pursuant to ASX Listing Rule 17.1, Mesoblast Limited ACN 109 431 870 (ASX: MSB; NASDAQ: MESO) (the Company) requests a trading halt in its securities effective immediately pending an announcement by the Company in relation to the United States Food and Drug Administration's review of its Biologics License Application for RYONCIL® (remestemcel-L) in pediatric patients with steroid-refractory acute graft versus host disease.

For the purposes of Listing Rule 17.1, the Company provides the following information:

- (a) the trading halt is requested pending an announcement in relation to the matters above;
- (b) the Company requests that the trading halt continues until it makes an announcement regarding the matters above which is expected to be on Monday, 5 October 2020; and
- (c) the Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Yours sincerely

Niva Sivakumar Company Secretary

Mesoblast Limited